New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?

Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nect...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Urologic oncology 2021-10, Vol.39 (10), p.619-622
Hauptverfasser:	Hoffman-Censits, Jean, Lombardo, Kara, McConkey, David, Hahn, Noah M., Bashir, Babar, Kelly, Wm. Kevin, Johnson, Burles, Matoso, Andres
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Bladder cancer Enfortumab vedotin Female Humans Male Nectin-4 Upper tract urothelial cancer Urologic Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	622
container_issue	10
container_start_page	619
container_title	Urologic oncology
container_volume	39
creator	Hoffman-Censits, Jean Lombardo, Kara McConkey, David Hahn, Noah M. Bashir, Babar Kelly, Wm. Kevin Johnson, Burles Matoso, Andres
description	Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV.
doi_str_mv	10.1016/j.urolonc.2021.05.013
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2543704351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143921002192</els_id><sourcerecordid>2543704351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-35d04d7af3c938a0a9dbd890888bc07166d91113d6e5e5325859c468e6c468e73</originalsourceid><addsrcrecordid>eNqFkMFu3CAQhlHUKtkmeYRUHHuxA8bYOJdVtEqaSFF7aZUjYmGsZWXDFvBGPSXvkDfsk5TNbnrtBQb0_TPwIXRBSUkJbS7X5RT84J0uK1LRkvCSUHaEZlS0rKjqrvmQa9KKgtasO0GfYlwTQmtB6TE6YXWu2q6doedv8ISVMzj5jdXxCoPrfUjTqJZ4C8Yn6_AIeqWcjWPEvscB4sa7CG-pfLAxKacBZzC_KK1gsGrAencX8J-XV_y4Ugkbj58AT85A2PEGR497FeZn6GOvhgjnh_0U_by9-bG4Kx6-f71fXD8UmjU8FYwbUptW9Ux3TCiiOrM0oiNCiKUmLW0a01FKmWmAA2cVF7zTdSOgeVtbdoq-7Ptugv81QUxytFHDMCgHfoqy4jVrSc04zSjfozr4GAP0chPsqMJvSYncuZdreXAvd-4l4TK7z7nPhxHTcgTzL_UuOwPzPQD5o1sLQUZtIXsyNoBO0nj7nxF_AVb1miA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2543704351</pqid></control><display><type>article</type><title>New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hoffman-Censits, Jean ; Lombardo, Kara ; McConkey, David ; Hahn, Noah M. ; Bashir, Babar ; Kelly, Wm. Kevin ; Johnson, Burles ; Matoso, Andres</creator><creatorcontrib>Hoffman-Censits, Jean ; Lombardo, Kara ; McConkey, David ; Hahn, Noah M. ; Bashir, Babar ; Kelly, Wm. Kevin ; Johnson, Burles ; Matoso, Andres</creatorcontrib><description>Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2021.05.013</identifier><identifier>PMID: 34148797</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Bladder cancer ; Enfortumab vedotin ; Female ; Humans ; Male ; Nectin-4 ; Upper tract urothelial cancer ; Urologic Neoplasms - drug therapy</subject><ispartof>Urologic oncology, 2021-10, Vol.39 (10), p.619-622</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-35d04d7af3c938a0a9dbd890888bc07166d91113d6e5e5325859c468e6c468e73</citedby><cites>FETCH-LOGICAL-c365t-35d04d7af3c938a0a9dbd890888bc07166d91113d6e5e5325859c468e6c468e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.urolonc.2021.05.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34148797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoffman-Censits, Jean</creatorcontrib><creatorcontrib>Lombardo, Kara</creatorcontrib><creatorcontrib>McConkey, David</creatorcontrib><creatorcontrib>Hahn, Noah M.</creatorcontrib><creatorcontrib>Bashir, Babar</creatorcontrib><creatorcontrib>Kelly, Wm. Kevin</creatorcontrib><creatorcontrib>Johnson, Burles</creatorcontrib><creatorcontrib>Matoso, Andres</creatorcontrib><title>New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV.</description><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Bladder cancer</subject><subject>Enfortumab vedotin</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Nectin-4</subject><subject>Upper tract urothelial cancer</subject><subject>Urologic Neoplasms - drug therapy</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFu3CAQhlHUKtkmeYRUHHuxA8bYOJdVtEqaSFF7aZUjYmGsZWXDFvBGPSXvkDfsk5TNbnrtBQb0_TPwIXRBSUkJbS7X5RT84J0uK1LRkvCSUHaEZlS0rKjqrvmQa9KKgtasO0GfYlwTQmtB6TE6YXWu2q6doedv8ISVMzj5jdXxCoPrfUjTqJZ4C8Yn6_AIeqWcjWPEvscB4sa7CG-pfLAxKacBZzC_KK1gsGrAencX8J-XV_y4Ugkbj58AT85A2PEGR497FeZn6GOvhgjnh_0U_by9-bG4Kx6-f71fXD8UmjU8FYwbUptW9Ux3TCiiOrM0oiNCiKUmLW0a01FKmWmAA2cVF7zTdSOgeVtbdoq-7Ptugv81QUxytFHDMCgHfoqy4jVrSc04zSjfozr4GAP0chPsqMJvSYncuZdreXAvd-4l4TK7z7nPhxHTcgTzL_UuOwPzPQD5o1sLQUZtIXsyNoBO0nj7nxF_AVb1miA</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Hoffman-Censits, Jean</creator><creator>Lombardo, Kara</creator><creator>McConkey, David</creator><creator>Hahn, Noah M.</creator><creator>Bashir, Babar</creator><creator>Kelly, Wm. Kevin</creator><creator>Johnson, Burles</creator><creator>Matoso, Andres</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202110</creationdate><title>New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?</title><author>Hoffman-Censits, Jean ; Lombardo, Kara ; McConkey, David ; Hahn, Noah M. ; Bashir, Babar ; Kelly, Wm. Kevin ; Johnson, Burles ; Matoso, Andres</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-35d04d7af3c938a0a9dbd890888bc07166d91113d6e5e5325859c468e6c468e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Bladder cancer</topic><topic>Enfortumab vedotin</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Nectin-4</topic><topic>Upper tract urothelial cancer</topic><topic>Urologic Neoplasms - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoffman-Censits, Jean</creatorcontrib><creatorcontrib>Lombardo, Kara</creatorcontrib><creatorcontrib>McConkey, David</creatorcontrib><creatorcontrib>Hahn, Noah M.</creatorcontrib><creatorcontrib>Bashir, Babar</creatorcontrib><creatorcontrib>Kelly, Wm. Kevin</creatorcontrib><creatorcontrib>Johnson, Burles</creatorcontrib><creatorcontrib>Matoso, Andres</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoffman-Censits, Jean</au><au>Lombardo, Kara</au><au>McConkey, David</au><au>Hahn, Noah M.</au><au>Bashir, Babar</au><au>Kelly, Wm. Kevin</au><au>Johnson, Burles</au><au>Matoso, Andres</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2021-10</date><risdate>2021</risdate><volume>39</volume><issue>10</issue><spage>619</spage><epage>622</epage><pages>619-622</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34148797</pmid><doi>10.1016/j.urolonc.2021.05.013</doi><tpages>4</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 1078-1439
ispartof	Urologic oncology, 2021-10, Vol.39 (10), p.619-622
issn	1078-1439 1873-2496
language	eng
recordid	cdi_proquest_miscellaneous_2543704351
source	MEDLINE; Elsevier ScienceDirect Journals
subjects	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Bladder cancer Enfortumab vedotin Female Humans Male Nectin-4 Upper tract urothelial cancer Urologic Neoplasms - drug therapy
title	New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T05%3A53%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20and%20topics:%20enfortumab%20vedotin%20mechanisms%20of%20response%20and%20resistance%20in%20urothelial%20cancer%20%E2%80%93%20What%20do%20we%20understand%20so%20far?&rft.jtitle=Urologic%20oncology&rft.au=Hoffman-Censits,%20Jean&rft.date=2021-10&rft.volume=39&rft.issue=10&rft.spage=619&rft.epage=622&rft.pages=619-622&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2021.05.013&rft_dat=%3Cproquest_cross%3E2543704351%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2543704351&rft_id=info:pmid/34148797&rft_els_id=S1078143921002192&rfr_iscdi=true